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A. LIST OF ABBREVIATIONS 
 
ASC Adult Stem Cell 
CHF Congestive heart failure 
[Ca2+]i Intracellular Calcium Levels  
BMP Bone Morphogenitic Proteins 
CCM Cellular Cardiomyoplasty 
CGR8 Center Genome Research 8 
Cx43 Connexin 43, gap-junction protein 
EB Embryoid Body 
ECM Extracellular Matrix 
EPC Endothelial Progenitor Cells 
ESC Embryonic stem cells 
FBS Fetal Bovine Serum 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
G-CSF Granulocyte Colony-Stimulating Factor 
GFP Green Fluorescent Protein 
HSC Hematopietic Stem Cell 
LIF Leukemia Inhibitory Factor  
MEF2C Myocyte Enhancer Factor 2C 
MHC Myosin Heavy Chain 
                MLC2a Atrial Myosin Light Chains  
MLC2v  Ventricular Myosin Light Chains 
MRI Magnetic Resonance Imaging 
MSC Mesenchymal Stem Cells 
PBS Phosphate Buffered Saline 
rCMC Rat Cardiomyocytes 
SPIO Superparamagnetic Iron Oxide 
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Introduction et résumé  (en français) 
L’insuffisance cardiaque est une maladie multifactorielle qui résulte notamment 
d’un épisode hypoxique ou ischémique, d’une hypertension artérielle ou d’une 
cardiomyopathie. Ces pathologies conduisent à la perte de myocytes contractiles. 
L’hypertrophie limitée des ventricules qui tend alors à compenser la perte de la capacité 
contractile de l’organe n’est que transitoire et fait place à une défaillance progressive de 
la fonction du myocarde. Cette hypertrophie cellulaire est la conséquence du faible 
pouvoir mitotique des cardiomyocytes adultes, les cellules ventriculaires ayant quitté le 
cycle cellulaire peu après la naissance chez la souris comme chez l’homme (Ho et al., 
1993; Klug et al., 1996).  
Le concept de « médecine regénérative » implique la possibilité de réparer un 
organe ou un tissu endommagé par l’injection de cellules souches qui ont préalablement 
été différenciées dans le type cellulaire à remplacer. 
L’isolement en 1998 de cellules embryonnaires pluripotentes humaines à partir d’un 
embryon surnuméraire au stade blastocyste (1 semaine après fécondation) a ouvert une 
perspective nouvelle de greffes cellulaires applicable à l'homme. Que sont-elles les 
cellules souches embryonnaires? Isolées à partir d'un embryon d'une semaine appelé 
blastocyste, elles se localisent au niveau de la masse interne du blastocyste. Elles se 
définissent pluripotentes car elles seront à l'origine de tous les tissus et organes du futur 
individu. Isolées chez la souris au début des années quatre-vingt par les études pionniers 
de Martin (Martin, 1981), leur potentiel a été depuis largement étudié comme modèle 
pour l'étude du développent mammalien, et plus particulièrement les déterminants 
génétiques de la morphogenèse du cœur.  
Déjà depuis 1996, Klug et coll. (Klug et al., 1996) ont utilisé des cellules 
embryonnaires souches pluripotentes (ou cellules ES) de souris, différenciées en 
cellules cardiaques pour les greffer dans un cœur sain de souris, montrant ainsi la 
faisabilité de cette approche de thérapie cellulaire. Depuis, plusieurs groupes ont élargis 
nos connaissance sur le destin des cellules d’origine diverse (embryonnaire, foetale ou 
adulte) implantées dans le myocarde sain ou endommagé (Dowell et al., 2003). 
La greffe de cardioblastes dérivés de ces cellules ES ou de cellules ES prédestinées 
à la lignée cardiaque dans un cœur défaillant permettrait, d’une part, une restauration du 
pouvoir contractile du ventricule et, d’autre part, fournir un système d’apport génique 
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sans le besoin de vecteurs adénoviraux qui restent encore problématiques en thérapie 
génique. En effet récemment, Min et coll. (Badorff et al., 2003; Di Nicola et al., 2002) 
ont implanté des cardiomyocytes, dérivés de cellules ES murines et manuellement isolés 
de cultures par microchirurgie, dans un modèle d'ischémie chez le rat. Malgré une 
récupération fonctionnelle du cœur, l'examen pathologique a quand même révélé la 
présence de cellules non différenciées dans les greffes. Plus récemment, Befahr et coll. 
(Behfar et al., 2002) ont montré que l'implantation de cellules ES murines non 
différenciées dans le cœur de rat résultait dans la spécialisation in situ de ces cellules en 
cardiomyocytes sans le besoin d'immunosuppression. Cette différenciation semblerait 
améliorer la fonction cardiaque, malgré un nombre très restreint d'animaux investigués, 
et résulterait de l'activation de la voie TGFβ par une action paracrine du cœur. 
D’autre part, la possibilité d’utiliser des cellules souches adultes pouvant être 
extraites de patient nécessitant d’une thérapie cellulaire, offrirait l’avantage de la 
parfaite compatibilité immunologique. Toutefois, le potentiel de transdifférenciation 
vers des phénotypes autres que celui pour lequel ils sont prédisposés semble être 
restreint et est actuellement un sujet controversé. Il est donc indéniable et indispensable 
que la recherche sur les cellules souches, soient-elles embryonnaires ou adultes, doit 
donc être poursuivie en parallèle. 
A présent, plusieurs voies d’administration ont été testées pour la greffe de cellules 
dans le cœur, telles que l’injection intramyocardique (Perin et al., 2003), intracoronaire 
(Strauer et al., 2002) ou intraveineuse (Kocher et al., 2001). Ces méthodes emmènent 
cependant à la perte de la majorité des cellules qui ne peuvent pas s’implanter dans un 
muscle en contraction, d’autant plus si présentant des territoires ischémiques et 
endommagés. Malgré cela, plusieurs études ont montré une amélioration de la fonction 
cardiaque, pour la plupart non explicable par le nombre restreint de cellules retrouvé par 
immunohistochimie (post-mortem). 
Ces dernières années, un nouveau concept faisant appel à l’ingénierie tissulaire est 
de plus en plus exploré. L’ingénierie tissulaire est basée sur l’incorporation de cellules 
dans des biomatrices d’origine naturelle ou synthétique, donnant un soutien structural 
aux cellules permettant ainsi la constitution in vitro de tissus tridimensionnels pour une 
transplantation fonctionnelle (Langer and Vacanti, 1993). L’incorporation de cellules 
dans des échafauds composés de polymères protéiques afin de reproduire l’organisation 
spatiale, mécanique et élastique du tissu natif représente un défi indéniable. Afin 
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d’épouser les contraintes d’un tissu générant un force contractile, les matériaux 
biodégradables tels que les hydrogels pourraient constituer un échafaud approprié pour 
la transplantation et l’intégration de tissus aussi complexes que le cardiaque. Les études 
récemment publiées incluent l’utilisation de matrices composées de polymères naturels 
tels que le collagène (Zimmermann et al., 2000) et la gélatine ou des polymères 
synthétiques biodégradables, par exemple à base d’alchool de vynyl ou d’éthylène 
(Holder et al., 1998). Ces biomatériaux présentent en outre la possibilité d’incorporer 
des facteurs de croissance ou des cytokines, utiles à la survie des cellules implantées et 
pouvant être libérées de façon contrôlée par les cellules mêmes. La création de 
matériaux bioactifs et biodégradables représente donc un champs de recherche majeur 
pour le contrôle de la différenciation des cellules souches et leur utilisation en thérapie. 
Un aspect important pour l’application et l’évaluation de la thérapie cellulaire est le 
développement de méthodes non- invasives permettant non seulement de suivre la 
migration cellulaire et la position des cellules après transplantation (biodistribution), 
mais aussi leur effet sur la fonction cardiaque. L’imagerie par résonance magnétique 
(IRM) émerge actuellement comme nouvelle discipline de choix pour la visualisation in 
vivo, la caractérisation et la mesure de processus biologiques à l’échelle cellulaire et 
moléculaire. Ces dernières années, l’IRM s’est imposée comme la méthode non 
invasive de choix pour la mesure quantitative de la contraction, de la perfusion tissulaire 
et de la viabilité myocardiques après injection d’un produit de contraste. Récemment, un 
champ d’investigation très intense en imagerie moléculaire concerne le développement 
de nouveaux produits de contraste IRM spécifiques, pouvant être introduits dans les 
cellules. Une classe de produits de contraste intéressants est constituée par des 
particules de fer superparamagnétiques (super paramagnetic iron oxide, SPIO), qui sont 
captées par les macrophages et les cellules du systèmes réticulo-endothélial. Ces 
produits de contraste à base d’oxydes de fer offrent la possibilité de marquage cellulaire. 
En effet, les particules d’oxyde de fer concentrées dans les cellules marquées vont 
perturber fortement l’homogénéité du champ magnétiques local et induire une forte 
chute de signal permettant la détection de ces cellules in vivo. La possibilité de suivre 
par IRM le devenir des cellules implantées ainsi que leur effet sur la fonction cardiaque 
est donc d’importance majeure. 
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Résumé 
Le but ultime de cette thèse a été de mettre au point des techniques d’ingénierie 
tissulaire pour la construction de tissus cardiaques en trois dimensions permettant la 
future implantation in vivo de ces « patches cardiaques » sur un myocarde endommagé 
par un infarctus.  
Nous avons donc premièrement étudié utilisé de biomatrices composées de gels de 
fibrine polymérisée dans lesquelles nous avons inséré des cellules souches d’origine 
diverse telle que les cellules souches embryonnaires de souris, les cardiomyocytes 
néonataux de rats ainsi que les cellules souches mésenchymateuses du sang du cordon 
ombilical humain. Nous avons par conséquent étudié le comportement de ces cellules 
dans un environnement en trois dimentions. 
Nous avons deuxièmement exploré le potentiel de transdifférenciation des cellules 
souches mésenchymateuses vers le phénotype cardiaques soit i) par traitement avec des 
agents déméthylants tels que la 5-azacytidine, soit ii) lors d’une coculture avec des 
cardiomyocytes néonataux de rat. 
Le troisième volet de cette thèse a consisté à mettre au point un protocole de 
marquage cellulaire par un produit de contraste composé de particules de fer 
superparamagnétiques (super paramagnetic iron oxide, SPIO) afin d’identifier les 
cellules ayant internalisé ces particules par imagerie à résonance magnétique (IRM).  
Les résultats obtenus ont permis d’établire les points suivants : 
1. Les cellules ES non-différenciées ou en différenciation dans des corps 
embryoïdes, ainsi que les cardiomyocytes néonataux peuvent être cultivés 
dans des gels tridimensionnels de fibrine ; 
2. Tels qu’établis, le simple traitement des hMSCs à la 5-azacytidine ainsi que 
la coculture avec des cardiomyocytes néonataux stimulent l’expression de 
gènes cardiaques tels que la MLC2 atriale mais ne suffisent pas pour enduire 
un phénotype cardiaque.  
3. Des agents de contraste à base de nanoparticules d’oxyde de fer (par ex. 
Resovist,) peuvent être utilisés sans dommage pour le marquage de 
différentes populations de cellules;  
4. Les premiers tests en IRM sur des gels 3D contenant des cellules marquées 
au fer nous ont permis d’identifier les cellules in vitro. 
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En conclusion, d’après nos résultats basés sur l’ingénierie tissulaire nous incitent à 
continuer le développement de cette stratégie de génération et implantation de 
« patches » cardiaques contenant des cellules pour la régénération cardiaque, comme 
alternative à l’injection conventionnelle de cellules en suspension. De plus, la possibilité 
de suivre de façon non-invasive la position ainsi que l’effet des cellules injectées par 
IRM représente une méthodologie de choix pour l’application de ces nouvelles thérapies 
cellulaires.  
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B. SUMMARY 
 
Stem cell-based therapies are an intensive field of research which hold a great 
promise for regenerative medicine. Embryonic stem cells (ESCs) have the potential for 
to differentiate into a variety of differentiated cells including cardiomyocytes. Stem 
cells isolated from adult tissues such as the bone marrow and the umbilical cord blood, 
also display some plasticity but the possibility to efficiently differentiate them into 
functional cardiac cells is still far away and object of intense investigation. Clearly the 
use of stem cells to regenerate contracting myocardium and improve immediate and 
long-term prognosis after acute myocardial infarction still faces several challenges, in 
particular the achievement of an optimal engraftment into the heart.  
Cardiac tissue engineering is an emerging promising strategy which relays mainly 
on the use of synthetic or biological matrix materials allowing the seeding of heart cells 
or stem cells to reconstitute contractile cardiac muscle-like tissues. The ultimate goal is 
to construct in vitro 3D “cardiac patches” that might be used in vivo for the regeneration 
of a diseased myocardium. Key issues are the choice of the suitable stem cells 
(embryonic and/or adult) and biomaterials for such a regenerative application. In order 
to study the positional fate upon implantation, molecular imaging such as magnetic 
resonance imaging (MRI) using contrast agents will be the discipline of choice for the 
non-invasive assessment of the myocardial response to stem cell therapy.  
Here, we studied the development of in vitro strategies involving tissue engineering, 
stem cells of different origin, as well as non-invasive cardiac imaging techniques (MRI) 
aiming at the future treatment of heart failure by cell therapy. Therefore, our research 
project is directed toward 2 specific aims: 
1. study the function of ESC and ASC seeded into 3D-fibrin gels to produce engineered 
cardiac patches. 
2. assess protocols for the labeling of stem cells with iron oxide nanoparticles  for MRI.  
Our results showed:  
• the feasibility of growing mouse ESC, differentiating ESC within embryoid 
bodies and neonatal cardiomyocytes into 3D-fibrin gels. Fibrin gels are a 
suitable material for the creation and the maintenance of cardiac cell networks, 
without affecting the function of beating CMCs. Cell density is a critical 
parameter for cell seeding into the fibrin gels.  
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• Demethylating agents such as 5-azacytidine to elicit the plasticity of hMSCs 
toward the cardiac phenotype allowed the expression of cardiac markers such as 
MLC2a. However, whether hMSCs from cord blood efficiently commit toward a 
cardiac phenotype either by chemical agents and/or by direct exposure to cardiac 
cells need to be further investigated. 
• Contrast media (i.e. Resovist, nanoparticles of iron oxide) could efficiently label 
our different cell populations without toxicity effects (demonstrated by Prussian 
blue staining, electron microscopy, spectrophotometry).  
• The first MRI assessment of 3D cell-engineered gels allowed us to identify the 
labelled cells in vitro. 
 
In conclusion, our results based on cardiac tissue engineering techniques will allow 
to pursue such an invaluable strategy for the improvement of in vivo cell transplantation 
of 3D cardiac patches into the heart, as an alternative to the conventional approach of 
injecting isolated cells. The non-invasive monitoring of cell migration and positional 
fate (biodistribution) after transplantation using MRI will be of great importance to 
assess the effect of such cell therapy.  
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C. INTRODUCTION 
1. Regenerative medicine in ischemic heart disease 
Ischemic heart disease especially myocardial infarction accounting for most of 
congestive heart failure, is the main cause of death in industrialized countries . Despite 
advances in surgical procedures, mechanical assistance devices, drug therapy and organ 
transplantation, more than half of patients with congestive heart failure (CHF) die 
within five years of initial diagnosis. Myocardial infarction typically results in non-
contractile fibrous scar formation and permanently impaired cardiac function because, 
after a massive irreversible cell loss due to ischemia, the myocardial tissue lacks 
intrinsic regenerative capability (Ho et al., 1993). 
Efforts to regenerate functional myocardial tissue are being firstly pursued through 
cell grafting (Klug et al., 1996; Koh et al., 1995a; Koh et al., 1995b), not only to 
regenerate viable cardiomyocytes but also to stimulate revascularization of the ischemic 
region by activating the neoangiogenesis and thus the survival stunned and hibernating 
myocardium.   
The concept of “regenerative medicine" consists in the possibility to repair damaged 
organs or tissues injecting stem cells which are firstly induced to differentiate into the 
required specific cell type. As illustrated in Figure A, embryonic stem (ES) cells have 
the capacity to differentiate into all cell types required for tissue repair. Since the 
isolation in 1998 of the first human ES cells (Thomson et al., 1998), hES allow for the 
first time 1) to study the genes involved in human development and 2) to find new drugs 
and assess their toxicity.  
The field of cell therapy has thus provoked a tremendous enthusiasm in researchers 
over the past few years. Studies on both animal and human stem cells (either embryonic, 
fetal or adult stem cells) have reported encouraging results, among which were obtained 
by stem cell grafting not only in animal models but also in the first clinical trials 
(Dowell et al., 2003; Menasche, 2003; Passier and Mummery, 2003). However, 
controversial results have been reported, indicating that still many scientific questions 
concerning the mechanisms involved in cell differentiation and tissue repairs remain to 
be solved. 
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Figure I. The promise of research on stem cells (from Stem Cells: Scientific Progress 
and Future Research Directions, National Institute of Health, 2001). 
 
 
2. Cell source for stem cell transplantation  
Till now, several groups have reported that cells of various origins, such as 
embryonic stem cells, skeletal myoblasts (Marelli et al., 1992; Taylor et al., 1998) bone 
marrow-derived mesenchymal stem cells, purified haematopoietic stem cells and 
endothelial progenitor cells etc, when implanted into models of myocardial infarction, 
they can improve the contractile function of the heart through cardiomyogenesis or 
angiogenesis (Chenite et al., 2000; Goodell et al., 2001; Orlic et al., 2001a; Orlic et al., 
2001b; Toma et al., 2002; Tomita et al., 1999).  
However, it appears difficult to efficiently direct the in vitro differentiation of both 
embryonic and adult stem cells, and to assess their in vivo function and fate. 
 
2.1. Embryonic Stem Cells (ESCs) 
In 1981, researchers reported methods for growing mouse embryonic stem cells in 
the laboratory (Evans and Kaufman, 1981).Only after nearly 20 years, investigators 
succeeded to isolate ESCs from human embryos generated by in vitro fertilization 
techniques (Thomson et al., 1995).  
Pluripotent ESCs can be obtained from two embryonic sources: 1) from the inner cell 
mass of the blastocyst (an embryo of 1 week of age), and 2) from gonadal ridges of the 
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fetus which provide the so called embryonic germ (EG) cells (Lagasse et al., 2000; 
Stewart et al., 1994). They are all defined as unspecialized cells that renew themselves 
for long periods through cell division and can be induced to differentiate to cells of all 
three primary germ layers (mesoderm, ectoderm and endoderm) under certain 
physiologic or experimental conditions. Thus, this unlimited differentiation capacity and 
indefinite propagation represent the strongest advantage of ESC.  
One goal of embryonic stem cell research is the development of specialized cells 
such as cardiomyocytes, endothelial cells etc for cellular cardiomyoplasty (CCM). The 
most common approach of directing differentiation is to change the growth conditions 
of ESCs in specific ways after removal of leukemia inhibitory factor (LIF) and 
fibroblast feeder cell layers. 
Indeed LIF and feeder cells promote and the division of undifferentiated ESCs and 
maintain their undifferentiated phenotype. To let the differentiation to start, cells are 
exposed to high concentrations of serum and are aggregated into embryoid bodies (EBs) 
through ‘hanging drop’ methods (Hescheler et al., 1997; Wobus, 2001). Here, cell-cell 
interactions in a three-dimensional environment are crucial to normal embryonic 
development both in vivo and in vitro. Intensive research is still needed to uncover the 
complex genetic pathways regulating a specific cell phenotype. 
ESCs-derived cardiomyocytes comprise diverse phenotypes including ventricular, 
atrial, sinus nodal, purkinje, and pacemaker-like cells, and can be easily identified in 
vitro by spontaneous contractile activity (Hescheler et al., 1997; Wobus, 2001). In vitro, 
yield can be improved by over-expression of the zinc-finger transcription factor GATA-
4 (Molkentin et al., 1994). Since only about 5% of the cells within EBs are 
cadiomyocytes, specific methods to isolate them from a complex mixture of cells are 
necessary. Indeed, ES-derived cardiomyocytes which are contaminated with other cell 
types can lead to the teratoma formation upon engraftment. Genetic methods allowing 
the sorting of cardiomyocytes include the use of a cardiac-specific promoter driving the 
expression of a fluorescent protein or of an antibiotic resistance cassette (Kolossov et 
al., 1998). Klug et al. was the first group to obtain pure murine ES-derived 
cardiomyocytes by stable transfection of a transgene comprised of the cardiac myosin 
heavy chain (MHC) promoter and a neomycin cassette, ant to engraft them into the left 
ventricular wall of dystrophic mdx recipient mice (Klug et al., 1996).  
Even though several protocols allow the generation of murine and human ES-derived 
cardiomyocytes, the isolation of a sufficient number of cardiac cell subtypes is not yet 
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efficient. Several drawbacks that still hinder the use of ESC in cell grafting, including 
immune rejection, the real integration of the injected cells with the native 
cardiomyocytes and ultimately the functional physiological activity of added cells on 
the cardiac function in vivo.  
 
2.2. Adult Stem Cells (ASCs) 
 Adult stem cells (ASCs) are poorly specialized cells that are present in a in several 
organs of the body and have the ability to get activated upon injury and specialize to 
repair the tissue in which they reside. Sources of ASCs include bone marrow, cornea 
and retina, brain, skeletal muscle, dental pulp, liver, skin, the lining of the 
gastrointestinal tract, and pancreas. The umbilical cord blood is also an abundant source 
of ASCs, with characteristics similar to the cells present in the bone marrow. 
Over the past several years, a new concept emerged - adult stem cell plasticity - that 
is the ability of an adult stem cell from one tissue to generate the specialized cell type(s) 
of another tissue. This phenomenon is referred to as “plasticity” or 
“transdifferentiation”. Figure II shows the preliminary evidence of plasticity among 
nonhuman adult stem cells. So far however, no isolated ASCs have been demonstrated 
to have the pluripotent capability of the ESCs, despite the observation of the appearance 
of several phenotypes in culture, although at extremely low efficiency. The in vivo 
reported plasticity of ASCs is relays on the observed integration of these cells into the 
host tissues and the assumption of some of its characteristics (Brazelton et al., 2000; 
Ferrari et al., 1998; Kocher et al., 2001; Mezey et al., 2000; Orlic et al., 2001b). 
 
2.2.1. Hematopietic Stem Cells 
They are two major types of ASCs found in bone marrow: hematopietic stem cells 
(HSCs) and stromal (mesenchymal) stem cells (MSCs). HSCs are widely recognized 
and used in clinical settings for their ability to self-renew and to give rise to all the kinds 
of blood cells in the body. Reports of human or mouse HSCs indicate their ablility to 
differentiate into 3 major types of brain cells (neurons, oligodendrocytes, and 
astrocytes), skeletal muscle cells (Ferrari et al., 1998)cardiac muscle cells (Kocher et al., 
2001; Orlic et al., 2001a) and liver cells (Alison et al., 2000; Gussoni et al., 1999; 
Theise et al., 2000). In the study by Orlic et al, purified, enriched HSCs populations can 
differentiate to vascular endothelium, smooth muscle cells and cardiomyocytes upon 
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direct transplantation into the infarcted heart (Orlic et al., 2001a). Another report 
showed that HSCs are also capable of homing to regions of ischaemic damages, where 
they contribute to both cardiac repair and neovascularization. However, in a very recent 
study, Murry et al demonstrated that HSCs do not transdifferentiate into cardiomyocytes 
in myocardial infarction areas (Murry et al., 2004). At the same time, Balsam et al 
thought that HSCs adopt only mature haematopoietic fates in ischaemin myocardium 
(Balsam et al., 2004). Taken together, the biological significance of HSCs homing and 
transdifferentiation into multiple distinct cell types following infarction still remain to 
be proven. There is a still long way to go in order to understand the molecular 
mechanisms regulating ASC plasticity.  
 
2.2.2. Mesenchymal Stem Cells 
 Mesenchymal stem cells (MSCs) are described as multipotent cells with 
multilineage differentiation capacity in vitro and in vivo, including fat, cartilage and 
bone, and skeletal muscle. They grow rapidly under the influence of mitogens such as 
platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and 
insulin-like growth factor-1 (IGF-1) (Bianco et al., 2001).  
 Some studies showed that the DNA demethylating agents such as 5-azacytidine 
applied on MSCs seam able to induce the appearance of the cardiomyocyte phenotype 
in culture (Hakuno et al., 2002). On the other hand, in vivo experiments indicated the 
MSCs as capable of cardiac engraftment and site-specific differentiation in myocardiac 
scar tissue in animal models of myocardial infarction. MSC-derived cardiomyocytes 
were identified by the presence of cardiac-specific genes such as α-cardiac actin, MLC-
2v and α-MHC (Toma et al., 2002; Tomita et al., 1999; Wang et al., 2000). 
Interestingly, it seemed that MSCs could avoid detection by the host immune system 
and obviate the need for immunosuppression even when allogenic stem cells are used 
(Di Nicola et al., 2002; Liechty et al., 2000). Although the MSCs may express a cardiac 
phenotype, whether MSCs could be truly recruited by the native myocardium and 
contribute to contractile function still need to be further assessed. Up to now, specific 
surface markers allowing the purification and the identification of MSCs or 
subpopulations of MSCs still need to be defined.  
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2.2.3. Endothelial Progenitor Cells  
Endothelial progenitor cells (EPCs) line the inner surfaces of blood vessels 
throughout the body. In a series of experiments in adult mammals, progenitor 
endothelial cells were isolated from peripheral blood (of mice and humans) by using 
antibodies against the surface markers CD34 and Flk-1, the receptor for VEGF 
(Yamashita et al., 2000). Bone marrow is also a source of endothelial progenitor cells 
(Asahara et al., 1997; Kocher et al., 2001). These cells are mononuclear blood cells and 
are referred to as MB-CD34+ cells and MB-Flk1+ cells. Another marker, CD133 has 
been also identified as expressed at an earlier time than CD34+ (Hristov et al., 2003). 
When plated in tissue-culture dishes, the cells attach to the substrate, become spindle-
shaped, and form tube-like structures that resemble blood vessels. When transplanted 
into mice of the same species (autologous transplants) with induced ischemia in one 
limb, the MB-CD34+ cells promoted the formation of new blood vessel (Asahara et al., 
1997). An attractive possibility is the possible trandifferentiaiton of EPCs into 
cardiomyocytes able to participate in myocardial regeneration (Badorff et al., 2003). 
 
 
 
Figure II. Preliminary evidence of plasticity among nonhuman adult stem cells (from 
Stem Cells: Scientific Progress and Future Research Directions. National Institute of 
Health, 2001). 
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2.2.4. Do cardiac stem cells exist ? 
Traditionally, human adult cardiomyocytes are defined as terminally differentiated 
cells which withdraw from the cell cycle and therefore loose their capacity of self-
renewal (Soonpaa et al., 1998; Soonpaa et al., 1997).The work for the Anversa group is 
challenging the field, launching the debate on the capacity of cardiomyocytes to 
undergo mitosis in the heart and showing that a sub-population of human 
cardiomyocytes divided after acute myocardial infarction (Beltrami et al., 2001). It still 
remain to be undoubtedly demonstrated that these cells arise from a resident cardiac 
stem cell population and not from circulating stem cells that have homed to the heart 
from a more distance site, such as bone marrow (Goodell et al., 2001). Oh et al reported 
that cardiogenic Sca-1+ (stem cell antigen-1) cells, isolated from the adult heart, 
displayed special surface markers distinct from hematopoietic stem cells, endothelial 
progenitor cells and muscle ‘‘satellite’’ cells. This cell population, if real, would offer 
auspicious properties for cardiac repair, including high levels of telomerase, homing to 
injured myocardium, and dependence on the well defined BMP (bone morphogenitic 
proteins) pathway (Oh et al., 2003). However, despite accumulating evidence for this 
phenomenon, the environment of damaged heart is such that it can’t substantially 
regenerate to face the need. 
 
2.2.5. Confusion between adult stem cell plasticity and cell fusion 
Although multiple laboratories have reported evidence of plasticity, several scientists 
raise a skepticism regarding these new findings. One of the principal arguments is the 
possibility of cell fusion to explain the observed transdifferentiation. Quite convincing 
evidence of cell fusion was demonstrated in two studies published simultaneously in 
2002 using neural or bone marrow stem cells, isolated from mice carrying both GFP and 
antibiotic-resistance genes (puromycin or G418), and co-cultured with ES cells in the 
presence of either puromycin or G418. After a few weeks, a small number of individual 
GFP-positive clones exhibited the potentiality of ESCs, but they were multinucleated 
and contained marker from both two cell types (Terada et al., 2002; Ying et al., 2002). 
One study reported evidence of fusion between bone-marrow-derived cells and Purkinje 
neurons, and between cardiomyocytes and hepatocytes (Alvarez-Dolado et al., 2003).  
While the truth is not as simple as what we presume, the resulting cell fusion event 
was evaluated as very rare, with a frequency of cell fusion among bone marrow stem 
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cells ranging from 2 to 11/1000’000 cells (Alvarez-Dolado et al., 2003), whereas 
transdifferentiation has been reported to occur in as much as 55% in coculture assays 
(Lagasse et al., 2000; Liu and Rao, 2003; Ying et al., 2002). Nevertheless, it has to be 
underlined that in nature, both differentiation and cell fusion are physiological 
mechanisms in osteoclast and skeletal muscle development (Krivokharchenko et al., 
2002; Rudnicki, 2003; Takami et al., 1999).  
 
  
2.3. “Homing” process of transplanted stem cells  
Transplanted stem cells undergo the process of “homing” when they are recruited to 
the site of injury. The underlying mechanisms and organ-specific differentiation signals 
regulating the homing are not clear so far. They may be related to the cell-cell adhesion 
and microenvironmental factors released from both heart and other distant organs such 
as the bone marrow. Those could favor migration, adhesion and differentiation of cells 
into mature cardiomyocytes. This hypothesis is based on the finding that injury tissue 
may cause the release of signals that circulate and induce mobilization of ASCs from 
the bone marrow pool and promote the expression of special receptors and ligands 
(Issarachai et al., 2002; Kawada and Ogawa, 2001; McKinney-Freeman et al., 2002). 
Several couples of receptor-ligand interactions have been described as follow. 1) 
Recent exciting evidence has reveled a central role for stem cell factor (SCF), c-kit, and 
matrix metalloproteinase-9 in the mobilization of stem and progenitor cells from bone 
marrow within hours of onset of myocardial necrosis (Heissig et al., 2002). 2) Receptors 
such as CXCR4 and its ligand stromal cell-derived factor-1 (SDF-1) are important for 
lymphocyte trafficking and recruitment at sites of inflammation after myocardial 
infarction (Pillarisetti and Gupta, 2001). It appears that CXCR4 serves as a chemokine 
receptor and together with its ligand, SDF-1, plays an important role in vasculogenesis 
(Salvucci et al., 2004)and hematopoiesis (Tavor et al., 2004; Zou et al., 1998). 3) Orlic 
et al (Orlic et al., 2001a; Orlic et al., 2001b)have shown that BMC, mobilized by SCF 
and G-CSF (granulocyte colony-stimulating factor), could home to the infarcted region, 
behave as cardiac stem cells, giving rise to cardiomyocytes, endothelial cells, and 
smooth muscle cells, ultimately promote myocardial repair. 4) Vascular endothelial 
growth factor (VEGF)/Flk-1 isoforms and the tyrosine kinase VEGF receptors have a 
clear role in endothelial cell proliferation and differentiation (Risau and Flamme, 1995). 
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For an optimal stem cell therapy of the heart, the role of these factors and cytokines 
have to be elucidated. 
 
2.4. Routes of delivery for cell therapy strategies  
Over the past years, several ways of engrafting stem cells into injured areas of the 
heart have been utilized both in human and in animal models, as described in table I, 
including intramyocardial injection (Perin et al., 2003), intracoronary injection (Strauer 
et al., 2002), and intravenous injection (Kocher et al., 2001). Direct intramyocardial 
injection may need fewer cells but requires a highly invasive intervention for the 
selection of the injection zone and is associated with intraoperative and postoperative 
risks. Data in animals indicate however that large quantities of engrafted stem cells are 
lost during and after this administration, including the unfavorable isckemic 
environment and the unability of the cells to be rapidly integrated in a contracting 
muscle.  
 A different approach is to implant stem cells through percutaneous catheter-based 
myocardial injections guided by electromechanical mapping, which can allow to 
identify scarred and viable myocardium and to assess the transmural extent of 
myocardial infarction in order to precisely target the injection into viable areas of 
stunning or hibernating myocardium (Tse et al., 2003). Presently, researchers are 
developing new techniques centered on tissue engineering strategies to regenerated the 
injured heart.  
 Table I. Routes of delivery in cell therapy (from Michael S. Lee, 2004). 
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3. Cardiac tissue engineering 
3.1. Tissue engineering 
Tissue engineering is a 10 year-old scientific field that combines principle from cell 
biology and engineering in order to create biologic replacement structures that restore, 
maintain, or improve tissue function (Langer and Vacanti, 1993). Tissue engineering 
involves the construction of tissue equivalents from donor cells seeded within three-
dimensional biomaterials, then culturing and implanting the cell-seeded scaffolds to 
induce and direct the growth of new, healthy tissue. The scaffold is biodegradable so 
that it can be removed and replaced over time. Tissue-engineering technologies have 
therefore the potential to revolutionize soft-tissue reconstruction by creating 
biologically-based tissue replacements. Tissue engineered skin, bone, and cartilage have 
been developed for use in patients, and heart valves (Neuenschwander and Hoerstrup, 
2004) and blood vessels (Koike et al., 2004; Remy-Zolghadri et al., 2004)have 
functioned well in several animal models.  
Cardiac tissue engineering methods rely mainly on the use of synthetic or biological 
matrix materials and heart cells or stem cells to reconstitute contractile cardiac muscle-
like tissue in vitro just like 3D “cardiac patches” that might be used for replacement of 
diseased myocardium in vivo. Typically it utilizes cells seeded into or onto polymeric 
scaffolds, reproducing the special organizational, mechanical, and elastic properties of 
native myocardium and represents a significant challenge from the perspective of tissue 
engineering scaffolds. Ideally, these constructs display properties of native myocardium 
such as coherent contractions, low diastolic tension, and syncytial propagation of action 
potentials. To be applicable for surgical repair of diseased myocardium engineered 
tissue constructs should have the propensity to integrate and remain contractile in vivo. 
In order to meet better the mechanical demands of force-generating contractile tissue, 
biodegradable materials such as hydrogels may serve as more appropriate scaffolds for 
the transplantation of organized cardiac tissue (Eschenhagen et al., 2002a; Nugent and 
Edelman, 2003; Zimmermann et al., 2000). Recent attempts to engineer soft tissues 
include the use of scaffolds manufactured from natural polymers, such as collagen 
(Zimmermann and Eschenhagen, 2003), gelatin, alginate (Burg et al., 2000) hyaluronic 
acid (Duranti et al., 1998), and chitosan (Chenite et al., 2000) gels or synthetic, 
biodegradable polymers (Brown et al., 2000; Holder et al., 1998). 
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3.2. Biomaterials 
Bioactive materials are materials that incorporate growth factors or cytokines and 
are able to release them either at a controlled ratio or directly on cell demand. 
Extracellular matrix (ECM) components like fibrin or collagen, or synthetic polymers 
mimicking the ECM, like the polyethylenglycol-modified polymers, can be used as 
vehicles for cell transplantation. These material offer the cells an environment providing 
adhesion natural sites, eventually growth factors and cleavage sites enabling the cells to 
substitute the material while proliferating and migrating. 
Native ECMs components such as fibrinogen from human plasma are particularly 
interesting since fibrinogen can be cleaved by thrombin into its fibrin subunits. After 
cleavage a self-assembly step occurs in which the fibrinogen monomer come together 
and form a non-covalently cross-linked gel via proteolytic exposure of binding sites. 
The covalent crosslinking of the chains is achieved via factor XIIIa, which is a 
trasglutaminase. Through factor XIIIa it was shown that other proteins like fibronectin 
or collagen can be bound (Hall et al., 2001; Schense and Hubbell, 1999; Ye et al., 
2000). 
By protein engineering it is possible to produce growth factors and cytokines, which 
have an alpha2-plasmin inhibitor sequence in their N-terminus. Gels containing such an 
architecture can trap growth factors and cytokines, which can be subsequently cleaved 
on cell demand (Schense et al., 2000; Zisch et al., 2001). Therefore, the degradation 
ratio of the gel as well as the release of growth factors will be cell proliferation-
dependent. 
Clearly, bioactive and biodegradable materials combined with tissue engineering 
represent a new leading field to improve stem cell differentiation, neoangiogenesis and 
electrical signal transduction. 
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4. Stem cell tracing using magnetic resonance imaging (MRI)  
An important aspect for the application and safety assessment of stem cells therapy is 
the development of non-invasive methods to monitor cell migration and positional fate 
of the cells (biodistribution) after transplantation.  
 
4.1. Role of imaging in stem cell therapy  
In preclinical trials, analysis of tissue specimens can be easily analyzed for the 
genetic and cells surface marker characterization. More and more, imaging techniques 
are emerging as important tools for the non-invasive assessment of the myocardial 
response to stem cell therapy through a serial imaging of myocardial function, 
perfusion, viability, and cell tracking at fixed time intervals.  
While, echocardiography is well established to measure myocardial function, it 
remains observatory dependant with a subsequent large variation for repeated exams in 
longitudinal studies (Hoffmann et al., 1996). Single photon emission computed 
tomography (SPECT) and positron emission tomography (PET) can also determine 
myocardial perfusion and metabolism. However, they are not able to resolve transmural 
analysis of the myocardium wall. In addition, dedicated set-up is needed for small 
animal imaging that are not widely available. Recently, magnetic resonance imaging 
(MRI) has emerged as a promising and recognized tool for cardiac imaging, as it will be 
further developed.  
MRI is generally accepted as a gold standard method for evaluating cardiac 
anatomy and volumes. Cine MRI provides excellent contrast between the myocardium 
and blood. The programmable nature of the imaging planes allows reproducible and 
volumetric coverage of heart. This leads to markedly smaller sample size than required 
by echocardiography (Al-Saadi et al., 2000; Kim et al., 2000). The technology also 
scales well with subject size from mouse to human. New MRI myocardial viability 
methods have been validated using contrast media as gadolinium chelates which induce 
a hyperenhancement of infarct myocardium (Kim et al., 2000). MRI assessment of 
viability correlates with PET for transmural infarct but appears to detect subendocardial 
infarction missed by PET (Klein et al., 2002).  
Recent developments have taken MRI beyond traditional anatomic and functional 
imaging. It is feasible to label cells with iron nanoparticles and detect their distribution 
in the body noninvasively. Gadolinium can be attached to antibodies for specific 
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labeling of compounds in vivo. Evenly, new contrast agents have made MRI 
visualization of gene expression at a cellular resolution (≈ 10µm). Two experiments 
showed that MRI detected and tracked separately intramyocardial injection of 
magnetically-labeled mesenchymal stem cells and catheter- based implantation of iron-
loaded myogenic precursor cells after myocardial infarction in swine models (Garot et 
al., 2003; Kraitchman et al., 2003).
 
4.2. Cell labeling by MRI contrast agents 
Since the in vivo uptake of MRI contrast media can not be tailored to any type of 
cells, usually ex-vivo cells are labeled using paramagnetic or superparamagnetic iron 
oxide (SPIO) contrast media. After implantation, the labeled cells destroy locally the 
magnetic field homogeneity. This results on dark spots that can be detected using 
dedicated MRI sequences (Pautler and Fraser, 2003). However, the assessment is 
largely qualitative based on the presence or absence of the dark spots. A quantitative 
assessment of the contrast media and cells distribution in the tissue remains a significant 
and largely unresolved challenge. 
Presently, two types of MR contrast agents are used clinically: gadolinium-
analogues and iron oxide nanoparticles particularly designed as blood-pool contrast 
agents who are impermeable to cells. Recently, superparamagnetic nanoparticles of 
anionic γ-Fe2O3  (iron oxide) have been shown to label efficiently different types of cells 
thanks to the negative surfaces charges. These particles are thus particularly suited for 
cellular imaging in vivo, due to a near-cellular (i.e. 20-50 microns) resolution, long half-
life and low local or systemic toxicity. However their uptake by cells still needs to be 
improved, for example using lipofection agents . A preferred magnetic labeling 
approach is based on the use of the FDA-approved SPIO formulation Ferridex, mixed 
with a transfection agent (Frank et al., 2002). A recent work by Hoehn et al used such a 
labeling to track GFP-expressing ESC (green fluorescent protein), by MRI upon 
implantation into an ischemic rat brain (Hoehn et al., 2002).  
In conclusion, feasibility for adult stem cell detection by MRI has been recently 
published. However, no data are available so far concerning embryonic stem cells. This 
technique of ESC labeling remains therefore to be developed to study in details the 
biodistribution of the cells after various types of engraftment.  
 
 24
D. MATERIALS AND METHODS 
 
 
1. Cells culture protocols 
 
1.1. Embryonic stem cell (ESC) culture and differentiation  
Mouse ESC CGR8 were cultured in BHK21 medium (GIBCO BRL) supplemented 
with nonessential amino acids, pyruvate, mercaptoethanol, glutamine, 
penicillin/streptomycin, 10% fetal calf serum and LIF-conditioned medium in a 
humidified 5% CO2 atmosphere at 37°C and maintained at < 70% confluency to keep an 
undifferentiated phenotype (Meyer et al., 2000).  
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Figure A. Colonies of undifferentiated mouse ESC. CGR8-ES clone is feeder cell-independent 
(no need of MEFs).Culture and propagation is achieved in the presence of LIF. 
 
 
The day of the injection procedure, cells were harvested by trypsinization, washed 
and pelleted, then suspended at a concentration of 2x107/ml in serum-free culture 
medium. The differentiation of CGR8 cell was performed by the hanging drop method 
(Maltsev et al., 1994).  
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Figure B. Cardiac cell differentiation by hanging drop method, and isolated by Percoll gradient 
centrifugation.                 
 
 
As illustrated in Figure B, EBs were formed at day 2 in hanging drops (450 
cells/20µl) of differentiation medium (BHK21, as described above), containing 20% 
fetal calf serum and lacking of LIF. After 6 days in suspension culture EBs were plated 
to gelatin-coated 24-well plates or cover slips (Meyer et al., 2000). The beating 
cardiomyocytes within EBs were counted under phase-contrast microscope at day 8 of 
differentiation. 
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Figure C. Sequence of pictures illustrating the passage from ESC to EBs in suspension then 
adherent EBs beat cardiomyocytes. 
 
                        
 
 
 
1.2. Isolation of ES-derived and neonatal mouse cardiomyocytes 
Day-8 EBs containing cardiomyocytes were detached from culture surfaces by 
incubating them with 0.05% trypsin-EDTA for 1 min at 37°C. Cells were dissociated 
with 1mg/ml collagenase (CLSII, Wortington), and 0.25% mg/ml pancreatin in a buffer 
containing (in mmol/L) NaCl 117, HEPES 20, NaH2PO4 1.2, KCl 5.4, Mg SO4 1, 
glucose 5, pH = 7.35. As shown in Figure D, myocytes were separated by centrifugation 
through a discontinuous Percoll gradient, and collected at the interface of the two layers. 
Neonatal cardiomyocytes were isolated from ventricles of 2 days-old mouse neonates 
using a similar method as previously described (Jaconi et al., 2000). 
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Figure D. Isolation of cardiomyocyte from day-8 EBs by enzymatic dissociation and 
centrifugation on a discontinuous Percoll Gradient. 
 
 
 
1.3. Human mesenchymal stem cells (hMSCs) culture  
Human MSCs (clone 102202-1) at passage 10 (p10) and hMSC-GFP (clone 102202-
1, have been transduced with a lentiviral vector pTK113 and FACS 100% GFP-
positive) at passage 11 (p11). Both cell lines have been isolated from human cord blood 
and were generously provided by Prof. Biagio Saitta from Coriell Institute for medical 
reset/ UMDNJ, New Jersey of USA. These cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, HG) (GIBCO) with 10% fetal bovine serum (FBS), 
2mM L-Glutamine, penicillin and streptomycin. They were seeded into 25-cm2 flasks 
and incubated at 37˚C in a CO2 incubator. The medium was changed every 2-3 days.  
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1.4. Treatment of hMSC with 5-azacytidine (DNA demethylating 
agent) 
  
Treated the culturing hMSC (passage11) with 5-azacytidine as described previously 
(Rangappa, 2003). 50,000 cells/ well were seeded in 6-well plates with and without 
coverslip, 120,000 cells/T25 flask, washed with phosphate buffered saline (PBS), then 
treated with different concentration of 5-azacytidine at 6,9,12 µmol/L and incubated for 
24 and 48 hours respectively at CO2 incubator (Table 1). Lately, the cells were washed 
and replaced with fresh DEME, HG culture medium and continue to incubate, observed 
daily, and the medium was changed every 2-3 days until the experiment was terminated 
at 3 weeks. 
 
           Table1. Condition of hMSC treatment with 5-azacytidine   
Incubation time                        Concentration 
24 hours 6µmol/L 9µmol/L 12µmol/L 
48 hours 6µmol/L 9µmol/L 12µmol/L 
 
 
1.5 . hMSC-GFP co-culture with rat neonatal cardiomyocytes 
Rat neonatal cardiomyocytes (CMC) were isolated following a well described 
protocol (Jaconi et al., 2000) and were cultured for 2-3 days. hMSC-GFP and neonatal 
CMC were mixed at a 1 :1 ratio and seeded in 24-well plates containing glass coverslips 
at a cell density of 40,000 /well. Just before seeding, neonatal CMC were treated with 
2µg/ml mitomycin for 40 minutes at 37˚C and then washed 3-4 times with PBS. Cells 
were co-cultured in CO2 incubator for 1 week. Changed medium every 2 days. The 
coculture cell mix was fixed and prepared for the protocol of immunofluorescence 
staining. Used antibodies and imaging examination by confocal microscope are 
described below. 
 
1.6. Immunofluorescence staining 
 hMSC were washed with PBS, then fixed with 1% paraformaldehyde for 15 
minutes at room temperature, and permeabilized with 0.1%Triton X-100. After blocking 
with 1% BSA in PBS, the hMSCs were incubated at 37°C for 1h with first monoclonal 
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antibodies (as described in table 2). TOTO-3 iodide 642/660 (Molecular Probes) and 
DAPI were used for nuclei dying with dilution of 1:1000. After being washed three 
times in PBS, coverslips were mounted on slides with Mowiol, dried overnight. 
Negative controls were performed with only second antibody. 
 
Table 2. Antibodies for immunofluoroscence staining 
First antibody Second antibody for MSC Second antibody for MSC-GFP 
anti-sarcomeric α-actinin 
1:100 (Sigma) 
anti-mouse IgG 1:200 
(FITC conjugate), (Sigma) 
Rabbit anti-mouse IgG Alexa 555  
1:1000 (Molecular Probes) 
anti-connexin-43 (mouse IgM 
isotype) 1 : 200 (Sigma) 
anti-mouse IgM 1:300 
(FITC conjugate), (Sigma) 
Rabbit anti-mouse IgM Alexa 555 
1:1000 (Molecular Probes) 
 
 
1.7. Confocal imaging 
Fixed immunostained hMSC were imaged on a Nikon inverted microscope (TE-
2000, objective 60x, 1.4 NA) using a Nipkow-type high speed confocal microscopy 
system (Ultraview RS, PerkinElmer, UK), as described (Tanaami et al., 2002). FITC 
fluorescence was excited at 488 nm by a Krypton/Argon triple line laser. The emission 
light (collected above 515 nm through a long-pass barrier filter) was imaged through a 
relay lens by an intensified high-speed 12bit cooled CCD camera (Orca ER). Z-
sectioning of the cells was performed using a piezo motor mounted on the objective (z 
step=0.2 µm). Images were recorded on a Dell computer.  
  
1.8. RNA extraction and RT-PCR analysis 
Total RNA of hMSC or other cell types were extracted using RNeasy®Mini Kit 
(QIAGEN, GmbH, Hilden, German). cDNA was synthesized from 1µg total RNA using 
3 µg random primers and 0.25µg oligodT. After a 2-minute duration at 70°C, then 4°C 
for 5 minutes, buffer containing 1µl dNTP mix  (10mM), 4 µl first stand buffer (5X 
from superscript kit), 1µl DTT (0.1M), 1µl superscript II 200U/µl were added to get a 
20µl final volume. Mixtures were put at 25°C for 10 minutes and reverse transcription 
was performed for 1.5 hours at 42°C, then diluted by H2O 5 times waiting till 4°C, and 
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stopped by heating 7 minutes at 72°C. cDNA samples were subjected to PCR 
amplification with primers as described in the table 3.       
 
Table 3. PCR Primer Sequences, Product Size and Conditions 
 
Gene 
product Sense Antisense 
Product size, 
bp Conditions 
GATA4 
Nkx2.5 
MEF2C 
MLC2v 
GAPDH 
Cx 43 
α-actinin 2 
MLC2a 
GACACCCCAATCTCGATATGTT 
GACATCCTAAACCTGGAACAGC 
CGTGGAGACGTTGAGAAAGAAG 
CAACGTGTTCTCCATGTTCG 
AGCCACATCGCTCAGACACC 
GGGTTAAGGGAAAGAGCGACC 
ACCATCATCCTTCGCTTTGCTA 
CAAGAAGCCTGAGCCTAAGAAG 
GGAGCTGCTGGTGTCTTAGATT
TTGTCCGCCTCTGTCTTCTC 
CCATCAGACCACCTGTGTTACC 
CAGCATTTCCCGAACGTAAT 
GTACTCAGCGCCAGCATCG 
CCCCATTCGATTTTGTTCTGC 
TCACGATGTCTTCAGCATCCA 
AGAACGTCTCAAAGTCCAGCAT 
400 
167 
328 
340 
300 
248 
301 
340 
35cycles, Tm 60° 
35cycles, Tm 60° 
30cycles, Tm 64° 
35cycles, Tm 60° 
25cycles, Tm 60° 
30cycles, Tm 56° 
30 cycles, Tm 57° 
39 cycles, Tm 61° 
            
For GATA4, MEF2C, MLC-2v and GAPDH amplifications, 2µl of the cDNA was 
added to the PCR mixture containing 3µl MgSO4, 1.5µl dNTPs (10mM), 2µl primer 
(10mM) and 0.4µl Taq Polymerase (QIAGEN). For Nkx2.5 amplification, 5µl Q 
solution (QIAGEN) was instead of 3µl MgSO4. 
For PCR, the performance consist of an initial denaturation at 94°C for 5 minutes, 
then 94°C for 1 minute, different Tm for 30 seconds, after 70°C for 1 minute, followed 
by different cycles (showed in table2), extension at 70°C for 7 minutes. Human 
GAPDH was as housekeeping gene, and human heart cDNA was used as positive 
control. The PCR products were size fractionated by 1.5% agarose gel electrophoresis.  
 
2. In vitro 3D-tissue engineering fibrin gels 
 
2.1 Fibrin gels and cells preparation 
 
 
Fibrin gel matrices were prepared by mixing the following components to the final 
concentrations: 10mg/ml fibrinogen (Fluka AG, Switzerland), 2U/ml factorXIII (Baxter 
AG, Vienna), 20 NIH units/ml thrombin (Sigma, St. Louis, MO) in 2.5mM CaCl2. 100µl 
fibin gel/well were put into the 8-well chamber slides or confocal dishes to construct the 
three dimensional matrix. The materials were kindly provided by P. Zammaretti, our 
collaborator at the Institute for Biomedical Engineering, Swiss Federal Institute and 
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University of Zurich (EPFZ) and EPFL. Murine ES cells, EBs, ES-derived CMC, 
neonatal CMC and hMSC were put in 3D gels composed of 0.2% fibrin respectively 
and monitored for morphological and differentiation changes. To assess morphological 
and functional changes of cardiomyocytes, both phase-contrast microscopy and 
confocal imaging of cytosolic free calcium changes were used.  
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Figure E. Engineered 3D fibrin gel with stem cells in vitro and prepareded this engineering 
tissue -“cardiac patches” implanted onto normal or infarcted rat hearts in vivo 
 
 
To monitor cells loaded with contrast agents using MRI techniques, cells were trapped 
in fibrin gels polymerized into 1cm cuvettes, with different layer compositions, as 
depicted in Figure F.
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Figure F. Composition of the fibrin gels and the labelled cells for the assessment of MRI in 
vitro. 
 
 32
2.2. Confocal imaging of intracellular calcium levels ( [Ca2+]i )  
Cardiomyocytes trapped in 3D fibrin gels or adherent on glass coverslips (2D 
cultures) were loaded with 5 µM fluo3 for 40 min, and transferred to the stage of an 
epifluorescence microscope and perfused with a medium containing 20mM HEPES, 
117 mM NaCl, 5.7 mM KCl, 1.2 mM NaH2PO4, 4.4 mM NaHCO3, 1.7 mM MgCl2, 1.8 
mM CaCl2, pH 7.4. Calcium changes were imaged on a Nikon inverted microscope 
(TE-2000, objective 60x, 1.4 NA) using a Nipkow-type high speed confocal microscopy 
system (Ultraview RS, PerkinElmer, UK), as described (Tanaami et al., 2002). FITC 
fluorescence was excited at 488 nm by a Krypton/Argon triple line laser. The emission 
light (collected above 515 nm through a long-pass barrier filter) was imaged through a 
relay lens by an intensified high-speed 12bit cooled CCD camera (Orca ER).  
To calculate the frequency of [Ca2+]c spikes displayed by the cells in the 3D gels, a 
region of interest was selected within a beating area and the average pixel intensity was 
plotted as a function of time. All experiments were performed at 35±2C°, under 
95%O2/5% CO2 atmosphere, and have been repeated on three separate occasions.  
 
 
3. Cell labelling by a MRI contrast agent (Resovist) 
We employed murine ES cells, ES-derived cardiomyocytes and human MSCs 
respectively. ES cells were cultured in the absence of LIF in a monolayer distribution. 
Labelling of the cells was achieved with MR contrast agent RESOVIST® (clinically 
used as liver contrast, 28mg/ml,Schering) which consists of ultrasmall 
superparamagnetic iron-oxide particles (USPIO). For this purpose, a transfection 
technique, generally used for the infusion of DNA into cell nuclei, was combined with 
the incubation of Resovist (transfection Kit-Effectene® , QIAGEN, Hilden, Germany). 
Following the manufacturer’s protocol to encapsulate the contrast agent, the cells were 
coincubate for from 24 hours to 48 hours, then washed by fresh culture medium, 
consequently facilitating the contrast agent infusion into the cells. Cells labelling 
without thansfection technique was also tested as a comparison. Iron particle inclusion 
into the cells was assessd by Prussian blue staining, spectrophotometric measurements 
(SYNCHRON CX® system, Beckman Coulter, Inc.) of the cellular uptake of USPIO, 
electron microscopy measurements (performed by Dr. M. Crèvecoeur from Dept. of 
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Botanics and Vegetal Biology University of Geneva) and ex vivo MRI (performed by 
Prof. Jean-Paul Vallée from Dept. Radiology Geneva University Hospital). For each 
experiment, cell preparations without transfection, with or without contrast agent 
treatment served as controls (see figure G). Effect of cell labelling on differentiation 
ability was assessed using ‘hanging drop’ method to induce ESCs differentiation into 
cardiomyocytes and assess the contraction areas and their beating frequency. To test the 
toxicity of Resovist in cardiomyocytes derived from ESCs, the morphological and 
functional changes were determined with the phase-contrast and confocal microscopy as 
above described.  
  
 
 
 
 
Figure G. Method and materials of cells labe ed by iron nanoparticles (Resovist) in vitro. 
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E. RESULTS 
 
 
1. In vitro 3D-tissue engineered fibrin matrices  
 
1.1. Culture of ES cells and EBs into fibrin matrices 
To study the behavior of undifferentiated murine ES cells into 3D fibrin matrices, 
we first used the CGR8 cells, an feeder-independent ES cell line, that were inserted into 
0.2% fibrin matrices polymerized into 8-well chamber slides (100 µl/well), as indicated 
in Fig.1 (panel a).Three-D gels were cultured in the absence of LIF for 2 days (Fig.1b 
and 1c). After 1 day, individual ES cells proliferated and formed small round clones (or 
clumps), which are supposed to be yet undifferentiated, as well as more flatten colonies 
with a differentiating phenotype.  At day 2, cells had further proliferated and formed an 
intense network of connected cells. Clumps of undifferentiated cells is decreased.  
To assess whether 3D fibrin gels can support the differentiation of ES cells, we first 
differentiated them within EBs using the hanging drop method.  
Four to six EBs at day 6 of culture were either adhered on top of individual 3D 
fibrin gels (referred as 2D cultures, Fig.2b), or were cultured into 3D fibrin gels 
(referred as 3D cultures, Fig.2c). These configurations were compared with the EBs 
adherent on gelatin-coated dishes (referred as controls, Fig.2a). After 2 days of culture 
(Day 8), clusters of contracting cardiomyocytes were observed in the 3 conditions. We 
found that the time of appearance and the frequency of contractions of the beating areas 
within the EBs in 2D and 3D culture were similar to the controls. For example 83±18.93 
beating/min in 2D, vs 80.25±18.37 in 3D and 84±18.82 in control conditions (n=8, 
representative experiment). However, the overall morphologies of EBs were different: 
in 2D cultures EBs easily kept a ball-like structure and remained more compacted 
indicating that they did not like to adhere to gelatin, as compared to in 3D cultures or 
control conditions, where EBs were more disperse and presented several ‘beating 
islands’.  
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Day 0 Day 1 Day 2
20X 10X 20X 
cba 
Figure 1. Murine ES-CGR8 cells were inserted into the 0.2% fibrin matrices (a) and 3D gels were 
cultured in the absence of LIF for 2 days (b, day1 and c, day2).  
cb
 
2D cultures ultures3D c
10X 
     Control 
 (gelatin-coated dishes) 
10X 10X 
a 
Figure 2. Day 6-EBs were either adhered on top of 3D fibrin gels (pannel b), (referred as 2D 
cultures), or were inserted into 3D fibrin gels (panel c) (referred as 3D cultures) compared with 
the EBs adherent on gelatin-coated dish (panel a).  
After 2 days of culture (Day 8), clusters of contracting CMCs were observed (dashed circles). 
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1.2. Culture of neonatal rat cardiomyocytes (rCMCs) into fibrin 
matrices 
When freshly-dissociated and purified neonatal rCMCs cells (>=2.5x105/gel) were 
inserted into 3D fibrin gels (Fig.3a), structures or interconnected organized into a 
network were observed after 4 days in 3D cultures (Fig.3b) and remained viable for up 
to 2 weeks, displaying functional networks of spontaneously beating cells (Fig.3c). 
Their contractility function was further confirmed by monitoring intracellular free 
calcium oscillations ([Ca2+]i ) in Fluo3-loaded single neonatal rCMCs using confocal 
microscopy as illustrated in Figure 4. Neonatal rCMCs adherent on gelatin-coated glass 
coverslips (Fig.4b) or within 3D fibrin gels (Fig.4c) displayed a similar calcium spiking 
activities (namely 117.6±50.31 and 97.2±20.01 spikes/min respectively). 
 
a 
10X 
cb
10X 4X 
Day 4 Day 14 Day 0 
Figure 3. Behavior of rat neonatal cardiomyocytes (CMCs) into 3D gels as a function of time. 
2.5x105 freshly-dissociated and purified CMCs (a) formed net-like structures after 4 days in 3D 
cultures (b), and remained viable for weeks in culture, displaying functional networks of 
spontaneously beating cells (b,c). 
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 38
1.3. Culture of human mesenchymal stem cells (hMSC) into fibrin 
matrices 
To study the behavior of hMSCs in three-dimensions, we cultured the cells into 3D 
fibrin gels at a density of 105 cells/gel, as illustrated in Figure 5. Cells migrated and 
aggregated into the 3D gels within 12 hours  (Fig. 5c,d and e), as compared to cells in a 
monolayer configuration (propagated on T25 flasks, Fig.5a). Aggregated hMSCs 
expressing GFP were followed by fluorescence within 3D fibrin gels (Fig. 5d) for up to 
weeks. When less cells than 105/gel were used (for ex. 5x104), no aggregation took 
place, indicating that the migration of the cells into fibrin was limited by the ability of 
hMSCs to digest the fibrin network in order to connect with neighboring cells. 
 
 
 
 
 
 
10X10X10X 
a b c
3D Control 
Day 1Day 0 
e
10X10X
d 
=
Figure 5. Behavior of hMSC in 3D fibrin gels. (a) Cells in a monolayer configuration (on T25 
flask); (b) cells inserted into 3D fibrin gels. Cell migration and aggregation was observed after 12 
hours (c). (d) Aggregated hMSCs expressing GFP were followed by fluorescence within 3D fibrin 
gels over time. 
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2. From hMSCs to cardiomyocytes: transdifferentiation ? 
 
 
2.1. Treatment of hMSCs with 5-azacytidine 
We decided to assess the transdifferentiation potential of hMSC derived from cord 
blood and provided our collaborator Prof. B. Saitta (NY, USA). To do this, we test the 
effect of a DNA demethylating agent, 5-azacytidine, which was reported to induce the 
appearance of cardiomyogenic cells in mouse and human MSCs from bone marrow and 
adipose tissue (Hakuno et al., 2002; Makino et al., 1999; Rangappa et al., 2003; Xu et 
al., 2004). 
Figure 6 shows the effect of 5-azacytidine treatment on hMSCs as a function of time 
(from 1 day to 3 weeks) and dose (6,9 and 12 µmol/l, treatment for 24 or 48 hours). 
Phase-contrast micrographs of hMSC treated for 48 hours, revealed identical cell 
morphology in control (Fig. 6A a,b) and treated cells, 1 day after the washout of 5-
azacytidine (Fig. 6A c,d). Binucleated cells were present in both treated and control 
cultures. At day 8, 5-azacytidine treatment resulted in a slower proliferation rate (Fig. 
6A e), as compared to control cells (Fig. 6A f). This dose response effect of 5-
azacytidine lasted until day 11 of culture (Fig. 6B). There was no difference in the 
overall morphology between 24 and 48 hours treatment. During 3 week observation, we 
could not identify any cells with a cardiac-like or myogenic-like phenotype, in contrast 
to what reported in the literature (Rangappa et al., 2003; Xu et al., 2004). In general, 
both controls and treated hMSCs displayed a short and rod-like morphology when 
seeded at relatively low density (about 5000 cells/cm2). At higher densities and at 
confluency, they tend to became elongated with a fibroblast-like shape. 
To assess the effect of 5-azacytidine on gene expression we looked for the possible 
induction of cardiac-specific transcription factors (such as MEF2C, GATA4 and 
Nkx2.5) or cardiac structural genes (such as atrial and ventricular myosin light chains, 
MLC2a and MLC2v). RT-PCR analysis, illustrated in Figure 7 and summarized in table 
1, revealed the expression of the cardiac-specific transcription factor MEF-2C, 
sarcomeres protein α-actinin and gap junction protein connexin43 in both untreated and 
treated hMSCs. This indicated that those markers were already present in hMSCs at 
least at the messenger level. In contrast, 5-azacytidine treatment was able to induce the 
mRNA expression myosin light chain 2a (MLC2a), at all concentrations tested if 
applied for 48 hours. 
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Figure 6. Effect of 5-azacytidine treatment on hMSCs as a function of time and dose. A) 
Phase-contrast micrographs of hMSCs after 1 day revealed no difference in morphology 
in control (a,b) versus treated cells (c,d). Bionucleation could be observed in both treated 
and control cells (black arrows). At day 8, 5-azacytidine treatment resulted in a slower 
proliferation rate treated cells (e) as compared to control cells (f). B) Dose response effect 
of 5-azacytidine after 11 days of treatment: (a)control, (b) 6µmol/l, (c) 9µmol/l, (d) 
12µmol/l. 
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Figure 7. Evaluation by RT-PCR of cardiac gene expression in hMSC treated or not with 5-
azacytidine. A) cardiac transcription factors (MEF2C, GATA4 and Nkx2.5) and B) cardiac 
proteins (α-actinin, MLC2a, MLC2v, Cx43). GAPDH as housekeeping gene. 
Lane 1: Human heart RNA as positive control  
Lane 2: Untreated hMSC 
Lane 3: hMSC treated with 6 µM 5-azacytidine for 24 hours 
Lane 4: hMSC treated with 9 µM 5-azacytidine for 24 hours 
Lane 5: hMSC treated with 12 µM 5-azacytidine for 24 hours 
Lane 6: hMSC treated with 6 µM 5-azacytidine for 48 hours 
Lane 7: hMSC treated with 9 µM 5-azacytidine for 48 hours 
Lane 8: hMSC treated with 12 µM 5-azacytidine for 48 hours 
Lane 9: H2O as negative control 
 
 
 Table 1. Visual evaluation of band intensities for the different marker tested by RT-PCR.  
 RT-PCR  
5-azacytidine 
treatment MEF2C α-actinin Cx43 MLC2a 
Control + + +  
6µM-24hrs + + +  
9µM-24hrs + + +  
12µM-24hrs ++ +++ ++ + 
6µM-48hrs +++ ++ +++ + 
9µM-48hrs + ++ + ++ 
12µM-48hrs + ++ + + 
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To further characterize hMSC and investigate the expression of markers at a protein 
level, cells were stained by specific antibodies and analysed by indirect 
immunofluoresence. Figure 8 depicted the immunolocalization of α-actinin and Cx43 in 
both treated and untreated hMSCs by confocal mircroscopy. Alpha-actinin in hMSC-
GFP had a spread distribution in the cytoplasm (Fig. 8b and 8c), similarly to Cx43 (Fig. 
8e and 8f). Neonatal rCMC served as the positive controls (Fig. 8a and 8b). 
 
 
 Figure 8. Immunolocalization of α-actinin and Cx43 in hMSC by confocal 
mircroscopy. a and d: neonatal rat CMCs, b,c,f: hMSC-GFP positive, e: 
control hMSCs. α-actinin in hMSC-GFP has spread distribution in the 
cytoplasm (b and c, white arrows), similarly to Cx43 (e and f, white arrow 
heads). α-actinin and Cx43 are revealed by Alexa fluor 555 secondary 
antibodies, except for panel e, where an anti-FITC antibody was used 
(nuclei are stained by ToTo3 in red). Confocal sections are of 0.2 µm. 
Scale bar:10 µm. 
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2.2. Co-culture of hMSC-GFP with rat neonatal cardiomyocytes 
 To investigate whether hMSC could be influenced by a direct contact with cardiac 
cells, we conducted coculture experiments in which hMSC-GFP were exposed to rat 
neonatal CMCs. When seeded at the same time, GFP-positive hMSCs aggregated to 
rCMCs and formed mixed clusters which displayed a contractile activity. However, if 
rCMCs were added on top of a monolayer of hMSCs, the coculture was not viable and 
all the rCMCs died because unable to adhere to such a configuration of hMSCs. In 
contrast, the opposite situation, i.e. hMSCs added on top of rCMCs where able to attach 
and gave the same results as the the coculture of cells seeded at the same time (data not 
shown). 
 Figure 9 illustrates phase-contrast and fluorescence micrographs of the rCMCs 
aggregated to hMSCs and clusters of contracting cardiomyocytes after 3 days of culture. 
We then looked at the expression of sarcomeric α-actinin and Cx43 in hMSCs 
cocultured with CMCs by immunocytochemistry. Figure 10 illustrates representative 
confocal images (single planes of 0.2 µm thickness) of α-actinin or Cx43 distribution in 
interacting hMSC and rCMC. Alpha-actinin resulted in organized z-lines (within 
sarcomeres) only in CMCs, while Cx43 localized in disorganized spots distributed 
between CMCs and hMSC.  
Figure 11 shows a 3D-reconstruction of confocal images for α-actinin distribution in 
hMSC-GFP cocultured with neonatal CMCs. Either these two types of cells aggregated 
together or overlaped with each other. It was hard to judge if hMSC still express α-
actinin after coculture.  
Interestingly, multinucleated MSC cells were frequently observed after one week of 
coculture (Fig. 12), and several nuclei, smaller than the one of isolated mononucleated 
cells, coexisted in single hMSCs. This suggested that cell fusion occurred either 
between hMSCs or between rCMCs and hMSCs.  
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Figure 9. Coculture experiments with hMSC-GFP and rat neonatal CMCs. 
Phase-contrast (a,b,c) and the corresponding GFP fluorescence micrographs (a’,b’,c’) after 3 
days of culture. Pictures show aggregation rCMC to hMSC and clusters of contracting 
cardiomyocytes (c-d, dashed circles). 
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Figure 10. Examples of α-actinin(a,c) and Cx43(b,d) stribution in hMSC-GFP cocultured with 
neonatal CMCs monitored by confocal microscopy. GF  is shown in green (FITC filters, α-actinin 
or Cx43 are stained in red by Alexa fluor 555 sec
blue/violet by Toto3 staining (60x, scale bar: 10 µm).  di
P
ondary antibodies). Nuclei are labeled in 
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Figure 11. 3D-distribution of α-actinin (red) in cocultures of rat neonatal CMCs and hMSC-GFP 
(a-d). Stacks of confocal images (0.2µm sections, 60X) are treated by Imaris. scale bar: 10 µm 
 
 
 
 
 
 
 
Figure 12. Multinucleation in hMSC after 1 week of culture with neonatal CMCs.  
Green: GFP; red: CMC nuclei stained by TOTO3 (objective 60X).  
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3. Cell tracking using MRI contrast agents 
 
3.1. In vitro cells labelling using Resovist 
In order to follow the positional fate of stem cells upon implantation by MRI 
techniques, we decided to define a protocol for labelling ES cells, ES-derived CMCs 
and hMSCs with Resovist, a contrast agent used in clinical setting for imaging of liver 
lesions (Muller et al., 1999). We adapted a previously published protocol used for 
labelling and tracing ES cells injected in the brain of rats (Hoehn et al., 2002). In 
particular, we tested iron particles of Resovist could be better endocytosed by 
coincubation with Effectene.  
We could efficiently label all the cells tested by Resovist and results are illustrated 
in Figure 13. We evaluated the intracellular iron concentration by spectrophotometry in 
ES cells incubated with Resovist in the presence of absence of effectene. A 
concentration of 9.3µg/ml Resovist with Effectene (corresponding to an iron 
concentration of 0.055mg/l) added for 24 hours was optimal condition. Indeed, the 
Effectene-mediated transfection increased the iron uptake to a final intracellular 
concentration of 1µM using 18.5 µg (1.85 µg/ml) Resovist. Instead, in the absence of 
Effectene, a 5 times higher concentration of Resovist (92.4 µg or 9.24 µg/ml iron) is 
needed to get the same final intracellular concentration of iron. The self-renewal and 
differentiation ability of ES cells were not affected by Resovist. 
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Figure13. Evaluation of the intracellular iron concentration by spectrophotometry in ES   
cells incubated with Resovist in the presence of absence of effectene. 
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Next, we wanted to test whether iron-labelled ES cells were still able to differentiate 
and commit to the cardiac phenotype. There was no difference in the morphology, the 
contractile areas and their beating frequency between EBs from iron-loaded ES cells 
and from control ES cells. Those three parameters were undistinguishable from the one 
of ES-derived CMCs loaded by Resovist. However, at the concentration above 28µg/ml, 
the differentiation of ES cells was inhibited. 
We first visualized the presence of iron particles by Prussian blue staining in 
undifferentiated ES cells. Blue iron particles were visible inside the cells by phase-
contrast microscope (Fig.14). Since we could not determine if the iron particle were all 
inside the cells or could also stick to cell membrane, we used electron microscopy to 
identify the intracellular localization of iron. As shown in Figure 15, iron particles were 
found in endocytic vesicles which appeared as black-stained. 
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Figure 14. Visualization by Prussian blue staining of iron particles internalized by ES cells after 
incubation with Resovist (white arrow heads). 
a: control ES cells. b: 9.3µg/ml Resovist without effectene. c: 9.3µg/ml Resovist with effectene. 
d: concentrations of Resovist higher than 56µg/ml inhibit cell growth and induce cell death. 
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Figure 15. The endocytosis of iron particles into vesicles was verified by electron   
microscopy  (panel a: control conditions, panel b: incubation with Resovist). 
 *: nucleus compartment;     endosomes;    mitochondria. 
 
We next assessed whether, upon staining of ES cells, iron particles were still visible 
8 days later within EBs. Pictures in Figure 16 illustrate that iron particles could be 
visible in EBs. Moreover, CMCs isolated from EBs could be efficiently stained with 
iron particles.   
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Figure 16. Visualization by Prussian blue staining of iron particles internalized by ES-
derived CMC after incubation with Resovist (white arrow heads). 
 a: Control EBs, b:EBs from iron-loaded ES cells   
 c and d: control ES-derived CMC without or with effectene treatement respectively.  
e: 6.3µg/ml Resovist + effectene f. 12.6µg/ml Resovist + effectene.  
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To exclude a toxic effect of iron, we measured [Ca2+]i in cardiac cells by live 
confocal microscopy. Figure 17 indicates that rhythmic fluctuations [Ca2+]i were similar 
to the one of unloaded cells.     
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Figure 17. Rhythmic intracellular free Ca2+ fluctuations in control (blue) or Resovist-treated 
(pink) ES-derived CMCs. Measurements are performed in single cells by confocal imaging. 
 
 
 
We then decided to apply our protocol for iron labelling to hMSC. When compared 
to the results observed with ES cells, hMSCs internalized more iron particles after 
Resovist incubation, as shown in Table 2, by spectrophotometry measurement. 
 
 
Table 2. Concentration of intracellular iron nanoparticles measured by spectrophotometry 
in hMSC incubated with increasing concentration of Resovist.  
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There was no visible difference in the morphology between controls and iron-loaded 
hMSCs. Figure18 shows Prussian blue staining of iron nanoparticles in hMSC cultured 
in monolayers. 
 
10X 10X 
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Figure 18. Prussian blue staining of hMSC incubated with Resovist. a: control; b: Resovist 
(9.3µg/ml) + effectene.  
       
When iron-labelled hMSCs (with 9.3µg/ml Resovist) were inserted into 3D fibrin 
gels, the iron appeared as a yellowish staining, moving together with hMSC inside the 
gels over time (Fig.19). This indicated that, if some particles are surface-bound, they do 
not seem to detach when the cells migrate inside the gels. It remains to be confirmed the 
intracellular localization of the iron particles by electron microscopy.  
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3.2. Assessment of iron-labeled cells by
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gels were inserted into cuvettes (as described incb
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 Material and Methods). We first imaged 
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by MRI increasing concentrations of Resovist into gels contained within the cuvettes. 
Figure 20 shows the MRI signals using 2 different sequences of detection. 
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Figure 20. In vitro MRI of different Resovist concentration within fibrin gels 
in plastic cuvettes. 1) 25 mg/ml Resovist, 2) 6.25 mg/ml, 3) 1.56 mg/ml, 4) empty gel 
(* in this condition the gel was detached and floated on top of the cuvette. 
The MRI sequence T2W/3D/Drive (a) is the most sensitive to the iron presence, while the sequence 
T2*/3D/FFE has the best dynamics(b). 
 
 
 
 
The MRI sequence T2W/3D/Drive (Fig. 20a) is most sensitive to the iron presence, 
while the sequence T2*/3D/FFE (Fig. 20b) has the best dynamics in the MRI 
experiment of different Resovist concentration within fibrin gels in plastic cuvettes. 
Subsequently, we imaged by MRI fibrin gels containing iron-labeled hMSCs. The 
cell-containing 3D gels were seen as a black band using the sequence T2*/3D/FFE (Fig. 
21 b), or as a white band using the sequence T2W FSE/3D/DRIVE (Fig. 21 c). 
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 Figure 21. In vitro MRI of hMSC within 3D-fibrin gels (0.2%) in plastic cuvettes. 
a. Control conditions (1: buffer, 2:empty gel, 3: gel with Resovist). 
b. hMSC loaded with Resovist are visible as a black band (red arrow) using the sequence 
T2*/3D/FFE). 
c. hMSC loaded with Resovist are visible as a white band (red arrow) using the sequence (T2W 
FSE/3D/DRIVE). 
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F. DISCUSSION 
 
This thesis focused on two major domains: cardiac tissue engineering and cell 
tracking using MRI. The present study first combined the potentialities of bioactive 
resorbable materials such as fibrin with the plasticity of stem cells in order to develop 
applications for heart tissue regeneration. We engineered 3D-fibrin gels as ‘cardiac 
patches’ containing undifferentiated ES cells, as well as ES-derived and neonatal CMC 
and adult stem cells such as MSCs from cord blood. We assessed their survival and 
function in vitro. Such an application of tissue engineering would represent a invaluable 
strategy for the improvement of in vivo cell transplantation into the heart, as an 
alternative to the conventional approach of injecting isolated cells. 
As a second aim, we tested the feasibility of using contrast media (i.e. nanoparticles 
of iron oxide) to label our different cell populations and monitor cell behavior such as 
survival, migration and function into 3D gels. The possibility to track the positional fate 
of such engineered cardiac patches using MRI will in the future allow us to assess their 
effect on heart function after transplantation onto the myocardium. 
Previous studies on heart tissue engineering reporting encouraging results mostly 
used neonatal CMC (Akins et al., 1999; Eschenhagen et al., 2002b; Zimmermann et al., 
2000). In this study, we investigated the in vitro behavior and function of 
undifferentiated ES cells, ES cells differentiating within EBs, ES-derived and neonatal 
cardiomyocytes, as well as adult stem cells (MSCs from cord blood) in a 3D 
environment composed of polymerized fibrin. 
 
Our findings raise several points that have to be taken into consideration: 
 
(1) The choice of fibrin as a scaffolds material for 3D-tissue engineering. 
The combination of fibrin and thrombin (two natural protein of the extracellular 
matrix) as main components of our porous gels, was first developed by Dr. A.H. Zisch 
as ‘seeding bed’ for endothelial progenitor cells (adherent EPC on top of polymerized 
fibrin gels) (Zisch et al., 2001). Compared to standard planar culture systems, cells 
inserted into 3D-fibrin gels (“cardiac patches”) acquired a peculiar spatial morphology. 
EBs remained more compact on the surface of the fibrin gels since fibrin reduced the 
ability to spread (Fig.2), neonatal rCMC formed small aggregates of contracting cells 
connected into a synchronously beating network ( Fig.3), while MSCs aggregated to 
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form tubular structures (Fig.5). However, cardiomyocytes could be identified into 
fibrin-trapped EBs at the same time point (generally day 8) as into EBs adherent on 
gelatin-coated surfaces (Fig.2). We therefore conclude that fibrin is a suitable matrix 
also for the differentiation of ES cells. 
Since we could not observe any difference in the frequency of [Ca2+]i oscillations 
displayed by CMC in 2D versus 3D cultures, we can conclude that fibrin gels are a 
suitable material for the creation and the maintenance of cardiac cell networks, without 
affecting the function of beating CMCs. Indeed, neonatal CMC could contract for 
longer times compared with the neonatal CMC on polystyrene culture dishes (McDevitt 
et al., 2003). 
The beating networks had a mechanical stability for up to 2 weeks before the 
degradation of fibrin by cell-released metalloproteinases (MPPs) (Spinale et al., 2000). 
Fibrin biodegradation by cells represents an advantage in vivo favoring homing and cell 
integration into the tissues. Clearly, in the future, other parameters such as the amplitude 
of [Ca2+]i spikes (using calibration procedures) or cell shortening should be assessed in 
CMC and also in ES-derived cardiomyocytes.  
Compared to what reported by Zimmerman et al which used neonatal rCMC into 
mechanically-stretched collagen strings (Zimmermann et al., 2004), our 3D gels 
allowed the cells to migrate and form structured beating aggregates. In contrast to 
collagen, fibrin is biodegradable and therefore allow to avoid the formation of adhesive 
tissue and fibrosis reaction on the surface of the heart in vivo.
Cell-to-cell contacts are crucial for the differentiation of ES in a 3D environment 
through the chemical and mechanical signals. McDevitt et al reported that patterned 
scaffold material might allow for guided cell growth and induce cardiacmyocyte 
differentiation (McDevitt et al., 2002). Whether cell stretch and 3D-geometric 
alignment of cells have an influence on differentiation of EBs need to be further 
investigated.  
 
(2) Culture conditions such as cell seeding  
 According to our observations using MSCs, at least 1x105 cells in 100µl gel 
(surface =0.9 cm2) are necessary to form the observed tubular structures (Fig. 5).  
For this gel volume, 5 EBs were the suitable number for the optimal differentiation and 
contraction of the differentiating cardiomyocytes. Unfortunately, ES-derived 
cardiomyocytes obtained in two preliminary experiments were not a pure population of 
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cardiac cells. For this reason, and due to the fact that cell yield was too low, we failed to 
observe cell migration and formation of cardiac networks. In the future, we propose to 
create a ES-cell line containing a cardiac promoter driving the neomycin cassette in 
order to isolate a pure population of cardiomyocytes by neomycin selection. 
Therefore, we conclude that cell density is a critical parameter for cell seeding in 
order to allow the formation of cell-cell contacts, the optimal diffusion of oxygen and 
cell nutrients. A limiting factor that should be assessed in the future is the maximal 
thickness allowed for the construction of 3D fibrin gels. This will be important for the 
future application of cardiac patches in the regeneration of the human heart. 
 
(3) Cells source for heart tissue engineering  
 The choice of the suitable cells for heart tissue regeneration is a critical issue. 
Normally, endothelial cells, fibroblasts, smooth muscle cells and macrophage comprise 
about 70% of the total cell number in the working myocardium (Nag, 1980) and 
undoubtedly play an important role in cardiac development and function (Gray et al., 
1998; Long et al., 1991; Shah et al., 1996), due to angiogenesis and secretion of growth 
factors and cytokines. When cardiac tissue engineering were constructed with a 
physiologic cell mixture consisting of cardiac myocytes and non-myocytes rather than a 
purified cardiac myocytes population, contractile function was markedly improved 
(Zimmermann et al., 2000). For the integration of cells such as new cardiomyocytes, the 
environment surrounding the cells had to favour the survival of the cells. For instance, 
3D gels offer the possibility to add cytokines or growth factors needed by the cells. One 
of our future aim will be to define 3D co-culture models including differentiating stem 
cells (embryonic or adult), together with non-myocytic cells of cardiac origin.  
 
Are adult stem cells such as MSCs from cord blood a suitable cell source for heart 
regeneration? Can these cells commit toward a cardiac phenotype either treated by 
chemical agents (5-azacytidine) and/or by direct exposure to cardiac cells? 
Our experiments with MSCs allowed us to drive the following observations: 
a) Control hMSC express the cardiac transcription factor MEF2C at the mRNA 
level as well as the sarcomeric protein α-actinin and Cx43 although localized in 
an unorganised manner (Fig. 8). This data was confirmed by mRNA microarray 
analysis of hMSC performed by our collaborator prof. Biagio Saitta. 
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b) We defined the conditions for the treatment hMSC with the demethylating agent 
5-azacytidine, able to induce the expression of the atrial form MLC2 at the 
mRNA level. However, no mRNA for the ventricular form of MLC2 was 
identified (Fig.7). Western blot analysis or immunofluorescence labelling will be 
required to identify the expression of MLC2a protein and its localization. More 
experiments are needed to assess whether hMSC may be really induced to 
differentiate towards a myogenic atrial phenotype by 5-azacitydine treatment.  
c) We didn’t found the formation of sarcomere-like structures nor any contractile 
cells within treated hMSC, questioning the myogenic differentiation potential of 
these cells. 
d) The observation of binucleated cells in both treated and non-treated cells (Fig.6) 
raises the problem of cell fusion during culture conditions and, ultimately, after 
transplantation in vivo. 
 
As future experiments, we propose to transduce hMSC with contructs containing 
Nkx2.5 or GATA4 transcription factors in order to assess the possible expression of 
cardiac proteins such as MLC2v in hMSC. 
Our coculture experiments with MSCs and CMC allowed us the following 
observations: 
i) hMSC failed to efficiently transdifferentiate into functional cardiac cells during the 
coculture period of 1 week, as observed by phase contrast and immunofluorescence 
staining (Fig. 9-11). 
ii) the observed multinucleated GFP-positive hMSC, with a decreased nucleus size 
approaching the one of cardiac cells (Fig.12), raised the question of cell fusion between 
these 2 cell populations. To prove this, nuclear markers such as chromosome staining 
will be needed.  
In conclusion, the isolation of hMSC is still a challenge for investigators due to 
several reasons such as the lack of specific surface markers, suitable stable culture 
conditions and so on. Further characterization of our hMSC will be needed. 
 
(4) Monitoring the engrafted stem cells by MRI. 
To deepen our understanding of role of stem cells in cardiac regeneration, the 
development of contrast agents for in vivo cell tracking and identification by MRI 
techniques will be of crucial importance for clinical applications. For this purpose, we 
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developed protocols for the in vitro labelling of stem cells including ES, ES-derived 
CMC and hMSC using the commercially-available agent Resovist (composed of 
nanoparticles of iron oxide). We assessed toxicity test and labelling efficiency of this 
contrast medium (using transfection agents), which differed as a function of the cell 
type (higher uptake by hMSCs as compared to the other cell types tested (Fig. 13 and 
table 2 ). 
The first MRI assessment of 3D cell-engineered gels gave encouraging results 
allowing us to identify the labelled cells in vitro (Fig.21). Future experiments will 
consist on implanting such cell-labeled 3D gels into rat hearts in order to identify them 
in vivo. This will be done in collaboration with the group of Prof. Jean-Paul Vallée. This 
work has been recently founded by the Leenaards foundation and will allow to pursue 
these experiments. 
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